JP2012522803A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012522803A5 JP2012522803A5 JP2012503725A JP2012503725A JP2012522803A5 JP 2012522803 A5 JP2012522803 A5 JP 2012522803A5 JP 2012503725 A JP2012503725 A JP 2012503725A JP 2012503725 A JP2012503725 A JP 2012503725A JP 2012522803 A5 JP2012522803 A5 JP 2012522803A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- composition
- crystalline form
- ornithine
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- 238000000034 method Methods 0.000 claims 16
- LRSYFEZBIMVWRY-VWMHFEHESA-N (2s)-2,5-diaminopentanoic acid;2-phenylacetic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CC1=CC=CC=C1 LRSYFEZBIMVWRY-VWMHFEHESA-N 0.000 claims 14
- 238000000634 powder X-ray diffraction Methods 0.000 claims 10
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 6
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims 3
- -1 alkali metal salt Chemical class 0.000 claims 3
- 230000001965 increasing effect Effects 0.000 claims 3
- 238000002844 melting Methods 0.000 claims 3
- 230000008018 melting Effects 0.000 claims 3
- 229940049953 phenylacetate Drugs 0.000 claims 3
- 239000005711 Benzoic acid Substances 0.000 claims 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 206010020575 Hyperammonaemia Diseases 0.000 claims 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 2
- 235000010233 benzoic acid Nutrition 0.000 claims 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 claims 2
- 229910052709 silver Inorganic materials 0.000 claims 2
- 239000004332 silver Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 claims 2
- UIQPERPLCCTBGX-UHFFFAOYSA-N 2-phenylacetic acid;silver Chemical compound [Ag].OC(=O)CC1=CC=CC=C1 UIQPERPLCCTBGX-UHFFFAOYSA-N 0.000 claims 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 229960003424 phenylacetic acid Drugs 0.000 claims 1
- 239000003279 phenylacetic acid Substances 0.000 claims 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 238000003825 pressing Methods 0.000 claims 1
- CLDWGXZGFUNWKB-UHFFFAOYSA-M silver;benzoate Chemical group [Ag+].[O-]C(=O)C1=CC=CC=C1 CLDWGXZGFUNWKB-UHFFFAOYSA-M 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000012312 sodium hydride Substances 0.000 claims 1
- 229910000104 sodium hydride Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16667609P | 2009-04-03 | 2009-04-03 | |
| US61/166,676 | 2009-04-03 | ||
| PCT/US2010/029708 WO2010115055A1 (en) | 2009-04-03 | 2010-04-01 | L-ornithine phenyl acetate and methods of making thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015031199A Division JP6010154B2 (ja) | 2009-04-03 | 2015-02-20 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
| JP2016237164A Division JP6328737B2 (ja) | 2009-04-03 | 2016-12-07 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012522803A JP2012522803A (ja) | 2012-09-27 |
| JP2012522803A5 true JP2012522803A5 (enExample) | 2013-05-16 |
| JP6144488B2 JP6144488B2 (ja) | 2017-06-07 |
Family
ID=42828717
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012503725A Active JP6144488B2 (ja) | 2009-04-03 | 2010-04-01 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
| JP2015031199A Active JP6010154B2 (ja) | 2009-04-03 | 2015-02-20 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
| JP2016237164A Active JP6328737B2 (ja) | 2009-04-03 | 2016-12-07 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
| JP2018079490A Expired - Fee Related JP6647336B2 (ja) | 2009-04-03 | 2018-04-18 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
| JP2020003346A Active JP7086118B2 (ja) | 2009-04-03 | 2020-01-14 | Ｌ－オルニチンフェニルアセテートおよびその製造方法 |
| JP2022049427A Pending JP2022088504A (ja) | 2009-04-03 | 2022-03-25 | Ｌ－オルニチンフェニルアセテートおよびその製造方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015031199A Active JP6010154B2 (ja) | 2009-04-03 | 2015-02-20 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
| JP2016237164A Active JP6328737B2 (ja) | 2009-04-03 | 2016-12-07 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
| JP2018079490A Expired - Fee Related JP6647336B2 (ja) | 2009-04-03 | 2018-04-18 | Ｌ−オルニチンフェニルアセテートおよびその製造方法 |
| JP2020003346A Active JP7086118B2 (ja) | 2009-04-03 | 2020-01-14 | Ｌ－オルニチンフェニルアセテートおよびその製造方法 |
| JP2022049427A Pending JP2022088504A (ja) | 2009-04-03 | 2022-03-25 | Ｌ－オルニチンフェニルアセテートおよびその製造方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (9) | US8173706B2 (enExample) |
| EP (4) | EP4101838B1 (enExample) |
| JP (6) | JP6144488B2 (enExample) |
| KR (6) | KR102123243B1 (enExample) |
| CN (3) | CN106810464B (enExample) |
| AU (1) | AU2010232521B2 (enExample) |
| BR (1) | BRPI1013657A2 (enExample) |
| CA (5) | CA2998434C (enExample) |
| CY (1) | CY1119843T1 (enExample) |
| DK (3) | DK3263100T3 (enExample) |
| EA (2) | EA034409B1 (enExample) |
| ES (3) | ES2652187T3 (enExample) |
| HR (2) | HRP20221232T8 (enExample) |
| HU (2) | HUE060371T2 (enExample) |
| IL (2) | IL215449B (enExample) |
| LT (2) | LT3686183T (enExample) |
| MX (4) | MX2011010262A (enExample) |
| NO (1) | NO2413924T3 (enExample) |
| NZ (3) | NZ619235A (enExample) |
| PL (2) | PL2413924T3 (enExample) |
| PT (2) | PT2413924T (enExample) |
| SG (3) | SG174982A1 (enExample) |
| SI (1) | SI2413924T1 (enExample) |
| SM (2) | SMT201700601T1 (enExample) |
| WO (1) | WO2010115055A1 (enExample) |
| ZA (1) | ZA201107189B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2319581E (pt) | 2004-11-26 | 2015-06-30 | Ucl Business Plc | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| CN106810464B (zh) | 2009-04-03 | 2019-01-22 | 欧塞拉治疗有限公司 | L-鸟氨酸苯乙酸盐及其制备方法 |
| ES2517340T3 (es) | 2009-06-08 | 2014-11-03 | Ucl Business Plc | Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato |
| US8068011B1 (en) | 2010-08-27 | 2011-11-29 | Q Street, LLC | System and method for interactive user-directed interfacing between handheld devices and RFID media |
| EP2625162B1 (en) * | 2010-10-06 | 2019-03-13 | Ocera Therapeutics, Inc. | Methods of making l-ornithine phenyl acetate |
| CN102993037B (zh) * | 2012-11-20 | 2015-03-04 | 南京工业大学 | 一种l-鸟氨酸苯乙酸盐的制备方法 |
| CN105481725B (zh) * | 2014-09-18 | 2019-01-22 | 博瑞生物医药（苏州）股份有限公司 | L-精氨酸苯乙酸盐的晶型及其制备方法 |
| KR20230018526A (ko) | 2014-11-24 | 2023-02-07 | 유씨엘 비즈니스 리미티드 | 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료 |
| HK1251149A1 (zh) | 2015-04-20 | 2019-01-25 | Ocera Therapeutics, Inc. | L-鸟氨酸苯乙酸盐制剂 |
| JP6990170B2 (ja) | 2015-08-18 | 2022-01-12 | オセラ セラピューティクス， インコーポレイテッド | Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防 |
| JP6989495B2 (ja) * | 2015-09-25 | 2022-01-05 | オセラ セラピューティクス， インコーポレイテッド | Ｌ−オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる神経細胞喪失の治療および予防 |
| US11219611B2 (en) * | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| WO2017083758A1 (en) | 2015-11-13 | 2017-05-18 | Ocera Therapeutics, Inc. | Formulation of l-ornithine phenylacetate |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| MX389665B (es) | 2017-05-11 | 2025-03-20 | Ocera Therapeutics Inc | Procesos para producir fenilacetato de l-ornitina |
| WO2019036471A1 (en) | 2017-08-14 | 2019-02-21 | Axcella Health Inc. | AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE |
| EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| CA3138914A1 (en) | 2019-05-09 | 2020-11-12 | Ocera Therapeutics, Inc. | Methods of assessing and treating hepatic encephalopathy |
| CN110707221B (zh) * | 2019-09-25 | 2023-09-01 | 北京大学深圳研究生院 | 氨基酸离子液体在制备钙钛矿光电器件中钙钛矿层的应用 |
| US12697317B2 (en) | 2019-10-16 | 2026-08-04 | Amalive Limited | Dosages and uses of ornithine phenylacetate for treating hyperammonemia |
| WO2023240081A1 (en) * | 2022-06-06 | 2023-12-14 | Yale University | Treatment, amelioration, and/or prevention of inflammatory and autoimmune diseases |
| WO2024261477A1 (en) | 2023-06-20 | 2024-12-26 | Yaqrit Limited | Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB965637A (en) | 1962-04-23 | 1964-08-06 | Tanabe Seiyaku Co | L-ornithine l-aspartate |
| NL302572A (enExample) | 1962-12-27 | |||
| GB1067742A (en) | 1963-09-16 | 1967-05-03 | Kyowa Hakko Kogyo Kk | Process for the preparation of l-ornithine l-aspartate |
| ZA716628B (en) | 1970-10-15 | 1972-06-28 | Richardson Merrell Spa | Composition and method for treatment of hepatic disease and mental fatigue |
| FR2113774A1 (en) | 1970-11-13 | 1972-06-30 | Roques Ets | Prepn of l-ornithine salts with org acids - using silver oxides |
| US4100293A (en) | 1974-04-15 | 1978-07-11 | The Johns Hopkins University | Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids |
| US3950529A (en) | 1975-02-03 | 1976-04-13 | Massachusetts General Hospital | Amino acid formulations for patients with liver disease and method of using same |
| US4320146A (en) | 1978-03-17 | 1982-03-16 | The Johns Hopkins University | Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids |
| US4228099A (en) | 1978-03-17 | 1980-10-14 | The Johns Hopkins University | Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders |
| US4352814A (en) | 1979-04-18 | 1982-10-05 | The Johns Hopkins University | Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs |
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US4857555A (en) | 1985-09-12 | 1989-08-15 | Brigham & Women's Hospital | Method of treating catabolic dysfunction |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US5139981A (en) | 1987-06-24 | 1992-08-18 | Union Carbide Chemicals & Plastics Technology Corporation | Process for preparing silver(I)-exchanged resins |
| JP2522034B2 (ja) * | 1988-12-27 | 1996-08-07 | 味の素株式会社 | α−ケト酸・アミノ酸塩化合物及びその製造方法 |
| JPH03273578A (ja) | 1990-03-23 | 1991-12-04 | Ricoh Co Ltd | 対物レンズクリーニング装置 |
| US5591613A (en) | 1990-07-02 | 1997-01-07 | Degussa Aktiengesellschaft | Method for the preparation of D-arginine and L-ornithine |
| DE4020980C1 (enExample) | 1990-07-02 | 1991-09-26 | Degussa Ag, 6000 Frankfurt, De | |
| JP3127484B2 (ja) | 1991-02-28 | 2001-01-22 | 味の素株式会社 | 肝炎治療薬 |
| US5767086A (en) | 1992-04-03 | 1998-06-16 | Terrapin Technologies, Inc. | Bone marrow stimulation by certain glutathione analogs |
| DK0659150T3 (da) | 1992-09-09 | 1997-09-29 | Fisons Plc | Farmaceutisk emballage. |
| US5571783A (en) | 1993-03-09 | 1996-11-05 | Clintec Nutrition Company | Composition and method for treating patients with hepatic disease |
| JP3273578B2 (ja) | 1993-09-21 | 2002-04-08 | 第一化学薬品株式会社 | オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法 |
| US6083953A (en) | 1994-07-28 | 2000-07-04 | Syntex (U.S.A.) Inc. | 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative |
| IL116674A (en) | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
| AU2251897A (en) | 1996-02-13 | 1997-09-02 | Trustees Of The University Of Pennsylvania, The | Method of treating liver disorders |
| ZA986614B (en) | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
| GB9815567D0 (en) | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| US6258849B1 (en) | 1998-07-23 | 2001-07-10 | Stanislaw R. Burzynski | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
| EP1179347A4 (en) | 1999-05-21 | 2002-06-26 | Takeda Chemical Industries Ltd | CONTROL SUBSTANCES FOR LIVER FUNCTION |
| US6768024B1 (en) | 2000-08-04 | 2004-07-27 | Lion Bioscience Ag | Triamine derivative melanocortin receptor ligands and methods of using same |
| JP3211824B1 (ja) | 2000-10-26 | 2001-09-25 | 味の素株式会社 | 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法 |
| JPWO2002074302A1 (ja) | 2001-03-15 | 2005-07-14 | 独立行政法人理化学研究所 | 肝機能障害改善用アミノ酸組成物 |
| US6503530B1 (en) | 2001-11-01 | 2003-01-07 | Chunghee Kimberly Kang | Method of preventing development of severe metabolic derangement in inborn errors of metabolism |
| US20030105104A1 (en) | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| CN1383815A (zh) | 2002-05-08 | 2002-12-11 | 刘万忠 | 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法 |
| US20040152784A1 (en) | 2002-07-23 | 2004-08-05 | Special Products Limited | Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia |
| JPWO2004019928A1 (ja) | 2002-08-30 | 2005-12-15 | 味の素株式会社 | 肝疾患治療剤 |
| US20050059150A1 (en) * | 2003-09-17 | 2005-03-17 | Becton, Dickinson And Company | Environments that maintain function of primary liver cells |
| MXPA03009902A (es) * | 2003-10-29 | 2005-05-03 | Manuel Francisco Lara Och Jose | Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio. |
| CA2556752C (en) * | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| JP4954867B2 (ja) * | 2004-05-06 | 2012-06-20 | オステオロジックス エイ／エス | 有機金属塩類を製造するための高収率で迅速な合成法 |
| US20060045912A1 (en) | 2004-08-30 | 2006-03-02 | Peter Truog | 4-phenylbutyric acid controlled-release formulations for therapeutic use |
| PT2319581E (pt) * | 2004-11-26 | 2015-06-30 | Ucl Business Plc | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| GB0426141D0 (en) * | 2004-11-26 | 2004-12-29 | Ucl Biomedica Plc | Treatment |
| RS53324B (sr) | 2005-11-17 | 2014-10-31 | Silverstone Pharma Est. | Stabilna formulacija amorfnih soli perindoprila, postupak za njihovu pripremu, naročito industrijsku pripremu, i njihova upotreba u terapiji hipertenzije |
| WO2007077995A1 (ja) | 2006-01-05 | 2007-07-12 | Kyowa Hakko Kogyo Co., Ltd. | 筋肉増量剤 |
| DE102007009243A1 (de) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
| CA2727088A1 (en) | 2008-06-04 | 2009-12-10 | Phenolics, Llc | Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same |
| CN106810464B (zh) | 2009-04-03 | 2019-01-22 | 欧塞拉治疗有限公司 | L-鸟氨酸苯乙酸盐及其制备方法 |
| AU2015221466B2 (en) | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| CA2763894A1 (en) | 2009-06-02 | 2011-01-13 | Salix Pharmaceuticals, Ltd. | Use of rifaximin to maintain remission of hepatic encephalopathy |
| ES2517340T3 (es) | 2009-06-08 | 2014-11-03 | Ucl Business Plc | Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato |
| AU2014250643B2 (en) | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
| JP2011236160A (ja) | 2010-05-11 | 2011-11-24 | Shinshu Univ | 非アルコール性肝疾患治療薬 |
| EP2625162B1 (en) * | 2010-10-06 | 2019-03-13 | Ocera Therapeutics, Inc. | Methods of making l-ornithine phenyl acetate |
| HUE036133T2 (hu) | 2012-11-21 | 2018-06-28 | Horizon Therapeutics Llc | Eljárások hepatikus enkefalopátia kezelésére szolgáló nitrogénelvonó gyógyszerek beadására és értékelésére |
| CN103705490B (zh) | 2013-10-31 | 2016-08-17 | 蚌埠丰原医药科技发展有限公司 | 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺 |
| KR20230018526A (ko) | 2014-11-24 | 2023-02-07 | 유씨엘 비즈니스 리미티드 | 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료 |
| HK1251149A1 (zh) | 2015-04-20 | 2019-01-25 | Ocera Therapeutics, Inc. | L-鸟氨酸苯乙酸盐制剂 |
| JP6990170B2 (ja) | 2015-08-18 | 2022-01-12 | オセラ セラピューティクス， インコーポレイテッド | Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防 |
| JP6989495B2 (ja) | 2015-09-25 | 2022-01-05 | オセラ セラピューティクス， インコーポレイテッド | Ｌ−オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる神経細胞喪失の治療および予防 |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| MX389665B (es) | 2017-05-11 | 2025-03-20 | Ocera Therapeutics Inc | Procesos para producir fenilacetato de l-ornitina |
| CA3138914A1 (en) | 2019-05-09 | 2020-11-12 | Ocera Therapeutics, Inc. | Methods of assessing and treating hepatic encephalopathy |
| US12697317B2 (en) | 2019-10-16 | 2026-08-04 | Amalive Limited | Dosages and uses of ornithine phenylacetate for treating hyperammonemia |
| IL297952A (en) | 2020-05-22 | 2023-01-01 | Ocera Therapeutics Inc | Uses of ornithine phenylacetate to treat hyperammonemia |
-
2010
- 2010-04-01 CN CN201710053850.1A patent/CN106810464B/zh active Active
- 2010-04-01 EA EA201500650A patent/EA034409B1/ru not_active IP Right Cessation
- 2010-04-01 KR KR1020197012203A patent/KR102123243B1/ko active Active
- 2010-04-01 BR BRPI1013657A patent/BRPI1013657A2/pt not_active Application Discontinuation
- 2010-04-01 NZ NZ619235A patent/NZ619235A/en unknown
- 2010-04-01 MX MX2011010262A patent/MX2011010262A/es active IP Right Grant
- 2010-04-01 PT PT107594426T patent/PT2413924T/pt unknown
- 2010-04-01 SI SI201031596T patent/SI2413924T1/en unknown
- 2010-04-01 JP JP2012503725A patent/JP6144488B2/ja active Active
- 2010-04-01 KR KR1020187008530A patent/KR101975726B1/ko active Active
- 2010-04-01 KR KR1020207016586A patent/KR102217081B1/ko not_active Expired - Fee Related
- 2010-04-01 CN CN201080021311.6A patent/CN102421432B/zh active Active
- 2010-04-01 EP EP22185562.0A patent/EP4101838B1/en active Active
- 2010-04-01 MX MX2018006692A patent/MX375111B/es unknown
- 2010-04-01 EP EP17185173.6A patent/EP3263100B1/en active Active
- 2010-04-01 MX MX2020009699A patent/MX388894B/es unknown
- 2010-04-01 EP EP20161306.4A patent/EP3686183B1/en active Active
- 2010-04-01 WO PCT/US2010/029708 patent/WO2010115055A1/en not_active Ceased
- 2010-04-01 SG SG2011071164A patent/SG174982A1/en unknown
- 2010-04-01 CA CA2998434A patent/CA2998434C/en active Active
- 2010-04-01 CA CA3077846A patent/CA3077846C/en active Active
- 2010-04-01 PL PL10759442T patent/PL2413924T3/pl unknown
- 2010-04-01 NZ NZ595706A patent/NZ595706A/en unknown
- 2010-04-01 MX MX2014008993A patent/MX356608B/es unknown
- 2010-04-01 HU HUE20161306A patent/HUE060371T2/hu unknown
- 2010-04-01 PL PL20161306.4T patent/PL3686183T3/pl unknown
- 2010-04-01 KR KR1020217004211A patent/KR102399540B1/ko active Active
- 2010-04-01 KR KR1020227016294A patent/KR20220067001A/ko not_active Abandoned
- 2010-04-01 DK DK17185173.6T patent/DK3263100T3/da active
- 2010-04-01 ES ES10759442.6T patent/ES2652187T3/es active Active
- 2010-04-01 CA CA2757373A patent/CA2757373C/en active Active
- 2010-04-01 SG SG10201406300YA patent/SG10201406300YA/en unknown
- 2010-04-01 HR HRP20221232TT patent/HRP20221232T8/hr unknown
- 2010-04-01 HR HRP20171962TT patent/HRP20171962T1/hr unknown
- 2010-04-01 LT LTEP20161306.4T patent/LT3686183T/lt unknown
- 2010-04-01 AU AU2010232521A patent/AU2010232521B2/en active Active
- 2010-04-01 CA CA2998344A patent/CA2998344C/en active Active
- 2010-04-01 EA EA201171216A patent/EA023051B1/ru not_active IP Right Cessation
- 2010-04-01 SM SM20170601T patent/SMT201700601T1/it unknown
- 2010-04-01 CA CA3205755A patent/CA3205755A1/en active Pending
- 2010-04-01 LT LTEP10759442.6T patent/LT2413924T/lt unknown
- 2010-04-01 ES ES20161306T patent/ES2928586T3/es active Active
- 2010-04-01 NO NO10759442A patent/NO2413924T3/no unknown
- 2010-04-01 DK DK10759442.6T patent/DK2413924T3/en active
- 2010-04-01 ES ES17185173T patent/ES2791524T3/es active Active
- 2010-04-01 HU HUE10759442A patent/HUE035921T2/en unknown
- 2010-04-01 NZ NZ708458A patent/NZ708458A/en unknown
- 2010-04-01 SM SM20220395T patent/SMT202200395T1/it unknown
- 2010-04-01 SG SG10202010988WA patent/SG10202010988WA/en unknown
- 2010-04-01 CN CN201410392027.XA patent/CN104230730B/zh active Active
- 2010-04-01 PT PT201613064T patent/PT3686183T/pt unknown
- 2010-04-01 KR KR1020117026256A patent/KR101844605B1/ko active Active
- 2010-04-01 EP EP10759442.6A patent/EP2413924B1/en active Active
- 2010-04-01 DK DK20161306.4T patent/DK3686183T3/da active
- 2010-04-02 US US12/753,763 patent/US8173706B2/en not_active Expired - Fee Related
-
2011
- 2011-09-30 ZA ZA2011/07189A patent/ZA201107189B/en unknown
- 2011-10-02 IL IL215449A patent/IL215449B/en active IP Right Grant
-
2012
- 2012-03-30 US US13/436,642 patent/US8492439B2/en active Active
-
2013
- 2013-07-08 US US13/937,107 patent/US8785498B2/en active Active
-
2014
- 2014-06-09 US US14/299,940 patent/US9034925B2/en active Active
-
2015
- 2015-02-20 JP JP2015031199A patent/JP6010154B2/ja active Active
- 2015-05-18 US US14/715,481 patent/US9604909B2/en active Active
-
2016
- 2016-12-07 JP JP2016237164A patent/JP6328737B2/ja active Active
-
2017
- 2017-03-24 US US15/469,359 patent/US10173964B2/en active Active
- 2017-12-20 CY CY20171101334T patent/CY1119843T1/el unknown
-
2018
- 2018-04-18 JP JP2018079490A patent/JP6647336B2/ja not_active Expired - Fee Related
- 2018-07-17 US US16/037,655 patent/US10550069B2/en active Active
- 2018-12-18 IL IL263784A patent/IL263784A/en unknown
-
2020
- 2020-01-14 JP JP2020003346A patent/JP7086118B2/ja active Active
- 2020-01-31 US US16/778,696 patent/US11161802B2/en active Active
-
2021
- 2021-11-01 US US17/516,591 patent/US12516015B2/en active Active
-
2022
- 2022-03-25 JP JP2022049427A patent/JP2022088504A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542935A5 (enExample) | ||
| JP2014524442A5 (enExample) | ||
| NZ742200A (en) | Treatment of osteoarthritis | |
| JP2015510010A5 (enExample) | ||
| JO3178B1 (ar) | النموذج السادس البلوري الجديد من مركب الاغوميلاتين وطريقة تحضيره وتحضير المركبات الصيدلانية المحتوية عليه | |
| JP2009517023A5 (enExample) | ||
| ME01831B (me) | Kristalni oblici 2-tiazolil-4-hinolinil-oksi derivata, snažni hcv inhibitor | |
| SI2902384T1 (en) | The form of ivabradine hydrochloride | |
| JP2012512197A5 (enExample) | ||
| RU2013158649A (ru) | Средство для ухода за зубами на основе ионов металлов с низким содержанием воды | |
| NZ596872A (en) | Improved method for synthesizing pirfenidone | |
| HRP20221232T1 (hr) | L-ornitin fenil acetat i postupci njegove pripreme | |
| JP2012528883A5 (enExample) | ||
| JP2013538849A5 (enExample) | ||
| TN2011000597A1 (en) | Non-caking salt composition, preparation process and use thereof | |
| GEP20094576B (en) | New cyrstalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| CN107129432B (zh) | 一种紫外线吸收剂4,4’－二已氧基二苯甲酮的合成方法 | |
| MX2010001705A (es) | Co-cristales de pirimetanilo y ditianona. | |
| RU2011150660A (ru) | L-сахарный агент, очищающий толстую кишку, и его применение | |
| WO2012024397A3 (en) | 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | |
| TW200610758A (en) | Alpha crystalline form of strontium ranelate, a process for its preparation, and pharmaceutical compositions containing it | |
| MD20120130A2 (en) | Delta crystalline form of the L-arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it | |
| KR20150109350A (ko) | 무기염의 제조 방법 및 무기염 생성물 | |
| JP2019524829A5 (enExample) | ||
| CN103787916B (zh) | 一种肟菌酯的制备方法 |